DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue S 1 · Volume 30 · January 1997 DOI: 10.1055/s-002-6366

Editorial

1
Linden, M.: Phase IV Research and Drug Utilization Observation Studies

Original Paper

4
Schäfer, H.: Post-Approval Drug Research: Objectives and Methods
9
Zaninelli, R.; Meister, W.: The Treatment of Depression with Paroxetine in Psychiatric Practice in Germany:
21
Laux, C.; Baier, D.: Quality-Monitoring of Psychotropic Drug Therapy in Post-Marketing Surveillance
28
Dittmann, R. W.; Linden, M.; Osterheider, M.; Schaaf, B.; Ohnmacht, U.; Weber, H.-J.: Antidepressant Drug Use: Differences between Psychiatrists and General Practitioners
35
Linden, M.; Baier, D.; Gothe, H.; Kohnen, R.: What Happens to Patients After the End of a Clinical Trial?
44
Schaaf, B.; Linden, M.; Weber, H.-J.: An Investigation of the Representativity of Neuropsychiatrists and their Patients in a Drug Utilization Observation Study on Fluoxetine
52
Lehmann, E.; Klieser, E.: Drug Monitoring Studies as a Method of Analyzing Response Criteria
57
Ahrens, B.: Mortality Studies and the Effectiveness of Drugs in Long-term Treatment
62
Herbold, M.: International Guidelines on Post-authorisation Research and Surveillance
65
Linden, M.; Baier, D.; Beitinger, H.; Kohnen, R.; Osterheider, M.; Philipp, M.; Reimitz, D. E.; Schaaf, B.; Weber, H. J.: Guidelines for the Implementation of Drug Utilization Observation (DUO) Studies in Psychopharmacological Therapy